Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

建業實業有限公司
Chinney Investments, Limited

(Incorporated in Hong Kong with limited liability)
(Stock Code: 216)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMMITTEES' MEMBER

The Board is pleased to announce that Dr. Vivian Wing-Kwong Chan has been appointed as an Independent Non-Executive Director of the Company, a member of each of Audit Committee, Remuneration Committee and Nomination Committee of the Company with effect from 3 November 2026.

The board (the "**Board**") of directors (the "**Director(s)**") of Chinney Investments, Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") announces that Dr. Vivian Wing-Kwong Chan ("**Dr. Chan**") has been appointed as an Independent Non-Executive Director of the Company, a member of each of Audit Committee, Remuneration Committee and Nomination Committee of the Company with effect from 3 November 2026.

Dr. Chan, aged 47, is the Managing Director of LHT Capital Limited, responsible for business development and investment management for a single-family office. She is the Founder of the Hong Kong PropTech Association, an industry organization dedicated to driving technology innovation and digital transformation across the real estate ecosystem, and a Council Member of the Smart City Consortium, where she chairs its PropTech Committee.

Dr. Chan holds several public and professional advisory roles and has over a decade of experience in finance and real estate. Her roles include serving on the Cyberport Entrepreneurship Committee Advisory Group and as a mentor for the Hong Kong Science Parks Corporation Startup Mentorship Programme and Cyberport Mentorship Services. She is a member of the Hong Kong Institute of Directors, the Hong Kong Professionals and Senior Executives Association, the Centum Charitas Foundation, and the Golden Bauhinia Women Entrepreneur Association.

Dr. Chan holds a Bachelor of Science in Business Administration from the University of Southern California, a Master of Science in Global Finance jointly awarded by The Hong Kong University of Science and Technology and New York University, and a Doctor of Business Administration from The Hong Kong University of Science and Technology. She is a Fellow Certified Practising Accountant (FCPA) of CPA Australia.

At the date hereof, Dr. Chan does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of Laws of Hong Kong). Save as disclosed above, Dr. Chan does not hold any other positions in the Company or any members of the Group, did not hold any directorships in any listed public companies in the past three years and does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company.

Dr. Chan has entered into a letter of appointment with the Company commencing 3 November 2026 which is terminable by either party by serving to another party one month's advance written notice. Her directorship is subject to retirement at the Company's next following annual general meeting, and thereafter retirement by rotation and re-election at the Company's annual general meeting every three years in accordance with the articles of association of the Company. Dr. Chan is entitled to a director's fee of HK$380,000 per annum which is based on the remuneration policy adopted for Independent Non-Executive Directors of the Company.

Dr. Chan has confirmed (i) her independence as regards to each of the factors referred to in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) she has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, there is no other information relating to Dr. Chan which is required to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

Taking this opportunity, the Board would like to extend its warmest welcome to Dr. Chan to the Board.

By Order of the Board
James Sing-Wai Wong
Chairman

Hong Kong, 3 November 2026

At the date of this announcement, the directors of the Company are Mr. James Sing-Wai Wong (Chairman), Mr. Yuen-Keung Chan (Vice Chairman), Mr. Raymond Ming-Joe Chow (Managing Director) and Mr. Winfred Wai-Lap Fan (Finance Director) as executive Directors; Dr. Emily Yen Wong as non-executive Director; and Mr. Richard Chi-Ho Lo, Mr. Randall Todd Turney, Mr. Stephen Henry Chu and Dr. Vivian Wing-Kwong Chan as independent non-executive Directors.